FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

Teva Pharmaceutical news from FiercePharma

News

Amgen profits drop, Teva's grow

It's a good news-bad news day on the earnings side, with Amgen reporting a drop in profits, but a boost in its 2008 forecast, and Ranbaxy earnings on the flat side, while Teva's are on the rise. Here Read more...

Teva seeks venture partner in Japan

Fresh off its $7.5 billion deal to buy Barr Pharmaceuticals, Teva is eyeing joint ventures in Japan. CEO Shlomo Yanai told the Financial Times that establishing a beachhead in that country is a top Read more...

Teva gets approval to buy Bentley

Teva Pharmaceutical Industries received nearly a 69 percent shareholder approval to complete its $360 million dollar purchase of Bentley Pharmaceuticals, a move the company hopes will help it to Read more...

It's Teva plus Barr in a $7.46B buyout

It's official: Teva and Barr are getting hitched. It's a $7.46 billion cash-and-stock deal that will combine the world's largest and fourth-largest generics makers into one big copycat drug Read more...

Rumor mill: Teva mulling $7.5B deal for Barr

The world's biggest generics firm may be about to get bigger -- lots bigger. Teva is reportedly in talks to buy Barr Pharmaceuticals for upwards of $5 billion; some reports quote a price as high as Read more...

Teva faces double Copaxone woes

Israeli generics giant Teva Pharmaceutical Industries is suffering a couple of Copaxone-related headaches. First, Israel's health ministry appointed a special committee to probe a trial of the MS Read more...

AstraZeneca wins Seroquel patent fight

AstraZeneca is celebrating today -- or at least relaxing a bit. It has avoided a full-blown trial today to protect its top-selling antipsychotic medication, Seroquel. The trial would have taken Read more...

J&J fights Teva with generic Risperdal

It's a watershed moment: Risperdal has gone generic. The Johnson & Johnson antipsychotic med now has copycat competition from Teva Pharmaceutical Industries, which got the final FDA go-ahead Read more...

Mylan to sell copycat of Teva MS drug

Here's a turnabout-is-fair-play story. Generics maker Teva Pharmaceuticals, known for its aggressive challenges to brand-name drugs, is getting challenged itself. The company has one very big branded Read more...

Vasella: 'Teva is better than we are'

Novartis CEO Daniel Vasella has a knack for the quotable quote. Here's the latest: "Teva is better than we are, and that's hard to Read more...